Biologics Market Size, Share and Growth Forecast 2026–2035

Biologics Market Trends for 2026

The biologics market size is projected to reach USD 1009.33 billion by 2035, growing from USD 522.06 billion in 2026, at a CAGR of 7.6% during the forecast period from 2026 to 2035.

Key Takeaways

• The biologics market will likely exceed USD 522.06 billion by 2026.
• Valuation is projected to hit USD 1009.33 billion by 2035.
• Estimated to grow at a CAGR of 7.6% starting from 2026 to 2035.
• North America held a major revenue share of 55% of the market in 2025.
• Asia-Pacific is expected to host the fastest-growing market in the coming years.
• By disease category, the oncology segment dominated the market by 40% share in 2025.
• By disease category, the hematological disorder segment is expected to expand rapidly in the market in the coming years.
• By source, the microbial segment held the led the market by 50% share in 2025.
• By source, the mammalian expression systems segment is expected to witness significant growth in the market over the forecast period.
• By manufacturing, the in-house segment accounted for the highest revenue share of 55% of the market in 2025.
• By manufacturing, the outsourcing segment is expected to grow with the highest CAGR in the market during the forecast period.
• By product, the monoclonal antibodies segment held a dominant revenue share of 45% of the market in 2025.
• By product, the antisense and RNAi therapeutics segment is expected to grow at the fastest CAGR in the market during the forecast period.

What are Biologics and What are Their Applications?

The American Cancer Society estimates 1.92 million new cancer cases and 609,360 deaths in the U.S., contributing to a global toll of 9.6 million lives lost in 2022. Biologics, monoclonal antibodies, and immunotherapies revolutionize cancer care, boosting survival and minimizing side effects.

Biologics are therapeutic products derived from living organisms or their components, such as cells, proteins, or nucleic acids. Unlike traditional drugs, which are often chemically synthesized, biologics are typically large and complex molecules produced using advanced technologies like genetic engineering. Biologics comprise diverse therapeutic products, including proteins, antibodies, vaccines, and other products produced through biological or biotechnology-based processes making them more targeted and specific in their actions. One significant aspect of biologics is their role in treating diseases at the molecular and cellular levels. They are designed to interact with specific biological pathways and mechanisms, making them highly effective in addressing the underlying causes of various diseases. Their target-specific mechanisms can provide clinically meaningful benefits for particular diseases, although efficacy and safety vary by product and indication.

The application of biologics spans a wide range of therapeutic areas. One prominent example is their use in oncology. Monoclonal antibodies, a biologic, have revolutionized cancer treatment by selectively targeting cancer cells while sparing healthy cells. This targeted action helps minimize damage to surrounding tissues and reduces side effects commonly associated with traditional chemotherapy. In autoimmune disorders, where the immune system mistakenly attacks the body's tissues, biologics can modulate specific immune response components. This helps to restore the balance and alleviate symptoms without suppressing the entire immune system, as is often the case with conventional treatments.

The growth of the biologics market is fueled by ongoing advancements in biotechnology, such as improved techniques for protein engineering and manufacturing processes. These innovations enable the development of novel and more sophisticated biological therapies. It's important to note that biologics often come with higher production costs and can be more challenging to manufacture than small-molecule drugs. This can result in higher prices for biological treatments. Despite this, the demand for biologics continues to rise due to their ability to provide effective and often life-changing solutions for patients facing various health challenges.

Additionally, the biologics market represents a transformative shift in medicine, offering targeted and personalized treatments that leverage the body's natural processes to address diseases at their roots. As research and development in biotechnology advance, we can expect further innovations and an expanding role for biologics in improving healthcare outcomes across diverse therapeutic areas.

Market Data & Statistics

• The DrugBank database contains 1,726 approved biologics, including proteins, peptides, vaccines, and allergenics.
• As of 2024, the U.S. Food and Drug Administration (FDA) has approved a total of 63 biosimilars across 17 unique reference products.
• About one-third of adults in the world are reported to have some form of chronic illness.

AI: A Catalyst for Growth in the Biologics Market

Artificial intelligence (AI) is poised to transform the biologics market by enhancing various stages of drug development and manufacturing. AI's integration promises to accelerate the discovery of biologics, including monoclonal antibodies and vaccines, by analyzing large datasets to identify promising candidates and predict their efficacy. Machine learning algorithms can streamline the drug discovery process, In selected workflows, machine-learning models can reduce manual analysis and support candidate prioritization, although performance depends on data quality and experimental validation.

In clinical trials, AI enhances patient recruitment by analyzing electronic health records and genetic data to identify suitable candidates, thus improving trial efficiency and success rates. AI also optimizes trial design and predicts patient responses, minimizing risks and enhancing data analysis.

During biologics production, AI-driven automation and predictive analytics improve process control and yield optimization. AI systems can monitor production processes in real-time, detect anomalies, and adjust parameters to maintain product quality. Additionally, AI aids in personalized medicine by analyzing patient data to tailor biologic therapies to individual needs, further expanding market opportunities.

For instance,

• In July 2024, Flagship Pioneering unveiled Abiologics, a company developing Synteins, a class of computationally designed and chemically synthesized biologics using novel building blocks beyond the 20 naturally occurring amino acids.

Biologics Market Trends and Future Outlook

• Expansion of Biosimilar Adoption: Biosimilars are gaining wider acceptance as patents for major biologic medicines expire. Healthcare providers are increasingly prescribing these cost-effective alternatives. Regulatory pathways are becoming clearer across many countries. Future growth will depend on broader approvals, stronger physician confidence, and improved patient access to affordable biologic treatments worldwide.
• Growing Demand for Personalized Biologics: Personalized biologic therapies are becoming more important for treating cancer, autoimmune disorders, and rare diseases. Better understanding of disease biology supports targeted treatment selection. Future development will focus on improving clinical outcomes, reducing side effects, and expanding personalized biologic options for larger patient populations across healthcare systems.
• Increasing Manufacturing Capacity Worldwide: Biopharmaceutical companies are expanding biologics manufacturing facilities to meet rising global demand. Investments in advanced production technologies and flexible manufacturing plants are improving supply reliability. Future expansion will support faster product availability, strengthen global supply chains, and increase access to innovative biologic therapies across emerging and developed healthcare markets.

Biologics Market Dynamics

Rising Demand for Biologics and the Crucial Role of Cost-Effective Biosimilars in Future Healthcare

The demand for biologics, which target specific pathways and cells in tough-to-treat areas like cancer and rare diseases, is on the rise. New modalities such as mRNA are broadening the scope of treatments available to patients and healthcare professionals. However, the high costs associated with developing these drugs often make them less affordable. This is where biosimilars come in. They provide similar treatments at a lower cost, helping patients and healthcare systems save money and allowing resources to be redirected to other areas of patient care.

Over the next decade, more than 55 blockbuster drugs, each with peak sales exceeding $1 billion, are expected to lose their exclusivity. This will likely spur increased competition among biosimilar companies. In this competitive landscape, Biosimilar developers face competition on regulatory timing, manufacturing cost, pricing, interchangeability, contracting, and provider adoption. However, as biosimilars start targeting more complex molecules and technological platforms, R&D expenses are expected to increase. This means that companies will need to focus even more on cost management to ensure their businesses remain sustainable.

• In 2024, FDA’s CBER reported 18 unique BLA approval entries on its annual BLA list; biological device applications are reported separately and should not be combined with BLA approvals.
• In 2023, FDA’s Center for Drug Evaluation and Research approved 55 novel drugs; FDA’s Office of Pharmaceutical Quality reported supporting 17 biotechnology products among those novel approvals.
• In 2023, CBER approved 20 biologics license applications, 23 biologics device applications, and 17 biologics license application supplements.

Global Burden of Chronic Diseases

In 2023, the World Health Organization (WHO) revealed that globally, WHO estimates that noncommunicable diseases cause 41 million deaths annually, equivalent to 74% of deaths globally. The burden of cancer, cardiovascular disease, diabetes, and other chronic conditions supports continued demand for long-term therapeutic options, including biologics where clinically appropriate. The leading causes of NCD-related deaths include cardiovascular diseases (17.9 million annually), cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, which includes deaths from diabetes-induced kidney disease).  The escalating prevalence of chronic diseases, such as cancer, autoimmune disorders, and diabetes, has spurred a surge in demand for effective and innovative treatment solutions worldwide. These persistent health conditions necessitate ongoing and targeted medical interventions, propelling the growth of the biologics market.

Biologics, crafted to interact with specific biological pathways within the body, exemplify their efficacy in managing the complexities of chronic diseases. In cancer treatment, they exhibit precision by targeting and inhibiting the growth of cancer cells. At the same time, in autoimmune disorders, they modulate the immune response to alleviate inflammation and prevent damage to healthy tissues. This targeted approach sets biologics apart from traditional drugs, offering precision and effectiveness that mitigates side effects often associated with broader-acting medications. As awareness of available treatment options grows, there is a rising patient demand for innovative therapies. Biologics' unique ability to address specific disease mechanisms aligns with these expectations, driving their adoption. Additionally, the long-term management requirements of chronic diseases find a fitting solution in biologics, as their targeted mechanisms of action make them well-suited for sustained use.

Biologics Drugs Used in Rare Diseases

The economic and social impact of the increasing burden of chronic diseases on healthcare systems underscores the urgency to find effective treatments that not only improve patient outcomes but also alleviate the overall economic strain. This imperative has fueled substantial investments in research and development within the biopharmaceutical industry, with pharmaceutical companies actively exploring and developing new biologics to meet the unmet medical needs associated with chronic diseases. In essence, the pervasive prevalence of chronic diseases is a pivotal factor propelling the biologics market forward, driven by the pressing demand for advanced, effective, and targeted treatments to address the challenges posed by these persistent health conditions.

The growing patient demand for innovative treatments, particularly in chronic health conditions, is a multifaceted trend shaped by several key factors. As individuals become more informed about available treatment options, they increasingly seek therapies that offer effectiveness, innovation, and personalization.

The Challenge Posed by Biosimilar Products

The advent of biosimilars has introduced a significant challenge to the established biologics market. Biosimilars, while similar in function to existing biologics, are different, and their entry into the market poses a threat to the market share and profitability of originator biologic manufacturers. Often entering the market at lower prices, biosimilars create pricing pressures that force original biologic manufacturers to reconsider their pricing strategies.

This intensified competition can result in a shift in consumer preferences and market dynamics as biosimilars gain acceptance. To navigate this challenge, biologic manufacturers must strategically adapt their approaches, potentially exploring innovations and new formulations or emphasizing superior efficacy and safety. Furthermore, educating healthcare professionals and patients about the unique benefits and proven track record of original biologics becomes crucial to maintaining trust and market presence. Legal considerations, such as protecting intellectual property and managing patent challenges, add another layer of complexity to the competitive landscape. Overall, the biosimilar challenge compels biologic manufacturers to engage in strategic initiatives to preserve their market position, emphasizing the need for adaptability and differentiation in the evolving pharmaceutical landscape.

Key Indicators and Highlights

Segmental Insights

By Disease Category Insight

Which Disease Category Segment Dominated the Biologics Market?

By disease category, the oncology segment held a dominant presence in the market by 40% share in 2025, due to the rising prevalence of cancer and growing research activities. Biologics treat oncology disorders by providing targeted action, resulting in fewer side effects. They offer superior advantages over conventional drugs and prevent cancer recurrence. The availability of biosimilars reduces economic burden on patients and their families due to cancer.

By disease category, the hematological disorder segment is expected to grow at the fastest CAGR in the market during the forecast period. Hematological disorders, such as certain inherited blood disorders, anemia, and hemophilia, pose a significant health burden on humans. Biologic therapies can address specific mechanisms involved in hematological disorders, with treatment effects varying by disease and product. Treatment of hematological disorders may involve biologics, blood products, plasma-derived therapies, or other interventions depending on the underlying condition.

By Source Insight

How the Microbial Segment Dominated the Biologics Market?

By source, the microbial segment held the largest revenue share of 50% of the market in 2025, due to advances in genetic engineering techniques and cellular biologics. Biologics are isolated from microorganisms, such as bacteria, fungi, and microalgae, using biotechnology methods and other cutting-edge technologies. Products, such as recombinant insulin, platelet-derived growth factor, and recombinant interferons, are some biologics that are derived from microbes.

By source, the mammalian expression systems segment is expected to grow with a significant CAGR in the market during the studied years. Mammalian expression is the system for studying the function of a particular protein in the most physiologically relevant environment. Mammalian-expressed biologics account for the greatest percentage of candidates in the biopharma pipeline. This is due to advances in cell-line development and cell culture technologies.

By Manufacturing Insight

Why Did the In-house Segment Dominate the Biologics Market?

By manufacturing, the in-house segment contributed the biggest revenue share of 55% of the market in 2025, due to the availability of favorable infrastructure and suitable venture capital investments. Investments allow biopharmaceutical companies to adopt advanced technologies for biologics research and manufacturing. In-house manufacturing enables manufacturers to provide complete control over their manufacturing process.

By manufacturing, the outsourcing segment is expected to expand rapidly in the market in the coming years. Small- and mid-sized biopharma companies lack sufficient infrastructure, necessitating them to outsource their research and manufacturing activities to contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). CROs/CDMOs have skilled professionals that provide relevant expertise and customized solutions to complex problems. 

By Product Insight

Which Product Segment Led the Biologics Market?

By product, the monoclonal antibodies segment led the market by 45% share in 2025, due to the growing need for immune-modulatory agents. Monoclonal antibodies (mAbs) are proteins that bind to a specific antigen responsible for disease progression. They are widely used due to their high specificity and selectivity, fewer side effects, and a longer half-life. FDA approvals of monoclonal-antibody therapies continue to add new treatment options across multiple therapeutic areas. In 2024, the U.S. Food and Drug Administration (FDA) approved a total 13 mAbs, out of 16 biologics.

By product, the antisense and RNAi therapeutics segment is expected to witness the fastest growth in the market over the forecast period. Antisense and RNAi therapeutics are emerging as prominent biologics for the treatment of various disorders, such as neurodegenerative disorders, genetic diseases, and respiratory disorders. They offer numerous advantages, including higher affinity due to chemical modifications, more stability, and reduced side effects due to off-target effects.

Regional Analysis

Driving Growth in North America's Biologics Market

Several factors contribute to the growth of the biologics market in North America. North America held a major revenue share of 55% of the market in 2025. One key reason is the high number of people dealing with long-term health issues. North America has many top biopharmaceutical companies, and the reimbursement policies for these advanced therapies are favorable. The use of biological prescriptions is increasing, and a lot of money is invested in developing targeted drugs, which is helping the market grow. Additionally, the approval of new and innovative biological drugs, like gene therapy and RNAi therapeutics, is expected to push the market further. In the North American map, places like Boston, San Francisco, and San Diego stand out as central hubs for these advancements, with numerous biotech companies, research centers and clinical trial sites contributing to the region's prominence in the biologics landscape.

U.S. Market Trends

U.S. held a CAGR of 7.10% in the Biologics Market in 2025. The Center for Biologics Evaluation and Research (CBER) regulates the approval of biologics in the U.S. The growing demand for biosimilars is likely to dominate the market. According to the report, expected launches and uptake could increase the overall spending on biosimilars to $20-$49 billion in 2027, with cumulative sales of $129 billion over five years.

Canada Market Trends

Canada is forecasted to grow to USD 36.27 billion in Biologics Market in 2026. Health Canada regulates the safety and effectiveness of biologics, including vaccines and biotechnology products. From 2020 to 2025, the Government of Canada invested more than $2.3 billion across 41 projects in the biomanufacturing, vaccine, and therapeutics ecosystem.

Navigating the Evolving Biologics Landscape in Asia-Pacific

APAC is expected to maintain a CAGR of 9.40% from 2026 to 2035 in Biologics Market. The geographical landscape of the biologics market in the Asia-Pacific (APAC) region has been dynamic and characterized by growth. Japan's well-established pharmaceutical industry has been a critical player in the APAC biologics market. The country has a robust regulatory framework and has seen the development and approval of various biologic drugs. India has a strong presence in the generic pharmaceutical market, and the biologics sector has been gaining traction. The country's biotech industry has been expanding, focusing on biosimilars. The COVID-19 pandemic has influenced biologics, with increased attention to biopharmaceutical research and vaccine and treatment development.

China Market Trends

China to crossed USD 64.08 billion by 2035 in Biologics Market. China has around 870,000 liters of active production capacity of biopharmaceuticals, ranking fifth in t he world. China ranks second in terms of the total number of biopharmaceutical manufacturing facilities, accounting for 209 facilities.

India Market Trends

India pushed the biologics market to USD 15.99 billion by 2026. India has 941,000 liters of active production capacity of biopharmaceuticals. India provides much of the world’s demand for biogenerics. The total annual turnover of pharmaceuticals in FY2024 was Rs 4.17 lakh crore, growing at an average rate of 10.1% in the last five years. India’s pharmaceutical exports are expected to grow from $27 billion in 2023 to $65 billion by 2030.

Why is the Biologics Market Growing in Europe?

Europe represents a mature market for blood pressure monitoring devices, supported by aging populations and widespread hypertension screening programs. Around 30–45% of European adults have hypertension, increasing routine monitoring demand. Healthcare providers encourage home blood pressure measurement alongside clinical assessments. Strong regulatory standards, growing digital health adoption, and continuous innovation in connected monitoring devices support sustained market development across the region.

UK Market Trends

The UK continues expanding home blood pressure monitoring through National Health Service initiatives aimed at early hypertension detection. More than 14 million adults are estimated to have high blood pressure. Pharmacies and primary care clinics actively promote self-monitoring for improved disease management. Increasing adoption of Bluetooth-enabled devices, rising public awareness, and supportive clinical guidelines are driving stronger demand for reliable monitoring solutions.

Germany Market Trends

Germany benefits from advanced healthcare infrastructure and high adoption of medical technologies for cardiovascular disease management. Nearly 20 million people in the country are estimated to have hypertension, encouraging regular blood pressure monitoring. Domestic and international manufacturers continue introducing innovative digital devices with enhanced accuracy. Strong reimbursement support, expanding preventive healthcare programs, and increasing demand from elderly populations contribute to steady market growth.

Latin America 

Latin America is growing at a significant rate in the market. The high spending on chronic conditions and enhanced regional convergence increase the demand for biologics. The growing contract outbound services and strong ecosystem for antibody discovery increase adoption of biologics. The proliferation of biosimilars and the easy availability of high-cost biological therapies drive the overall growth of the market.      

Brazil Market Trends 

Brazil is the strongest player in the market in the Latin America region. The growing prevalence of rheumatoid arthritis and domestic production incentives increase the adoption of biologics. The move to low-cost biosimilars and the surging protein purification technologies help with expansion. The need for injectable treatments and the development of primary biopharmaceuticals support the overall growth.    

Argentina Market Trends 

Argentina is growing steadily in the market. The established biotech sector and the increased biological approvals increase the production of biologics. The rising rate of psoriasis and the investment in regional cooperation projects increase the use of biologics. The growing monoclonal antibody sector and the established mRNA infrastructure boost the overall growth.     

Middle East & Africa 

The Middle East & Africa is growing at a substantial rate in the market. The use of specialized biologic treatments in non-communicable diseases helps with expansion. The increasing healthcare treatment costs and patient expiration of drugs increase the use of biologics. The burgeoning pharmaceutical localization and simplified approval pathways increase production of biologics. The investment in bioprocessing facilities drives the overall growth.    

Saudi Arabia Market Trends 

Saudi Arabia is rapidly growing in the market. The national biotechnology strategy and the high burden of genetic conditions increase the demand for biologics. The shift to advanced biologic therapies and targeted drug production helps with expansion. The demand for cost-effective treatments and the increased approval of precision therapies help with expansion. The adoption of high-cost biotechnology therapy supports the overall growth.     

United Arab Emirates Market Trends 

The United Arab Emirates is growing significantly in the market. The transition to advanced biological treatments and the personalized medicine initiative helps with expansion. The established vaccine facilities and the patient demand for complex therapy increase the use of biologics. The rise in advanced biomanufacturing technology boosts the overall growth.   

Competitive Landscape

The presence of established pharmaceutical companies and emerging biotechnology firms characterize the competitive landscape of the biologics market. The landscape is dynamic, with ongoing research and development, collaborations, mergers, and acquisitions shaping the industry. Companies often engage in collaborations and partnerships to enhance their biologics pipelines. Collaborations between big pharmaceutical and smaller biotech firms are typical for developing novel therapies. Mergers and acquisitions are prevalent in the biologics sector, allowing companies to expand their portfolios and strengthen their positions. The competitive landscape is influenced by product innovation, clinical trial success, regulatory approvals, and market expansion strategies.

Market Ecosystem Analysis

Value Chain Analysis – Biologics Market

R&D

The latest research of biologics is driven by advancements in genetic engineering techniques, leading to the development of innovative products.

Key Players: Twist Bioscience, Biocon Biologics, and WuXi Biologics.

Clinical Trials & Regulatory Approvals

Clinical trials are conducted to assess the safety and efficacy of biologics and identify their expanded application, which are then subsequently approved by regulatory agencies.

Key Players: MedPace, Syneos Health, Lindus Health, and Parexel.

Distribution to Hospitals, Pharmacies

Biologics are distributed to patients, healthcare professionals, and retail pharmacies through distributors or wholesalers.

Key Players: BioLogic, HC Biologics, and Millenium Science.

Biologics Market Companies

• Amgen
• Merck & Co.
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb
• Sanofi
• Bayer AG
• AstraZeneca
• GlaxoSmithKline Plc.
• Novartis AG
• Eli Lilly and Company

Market Share Influence Assessment

Competitive Landscape

Recent Developments in the Biologics Market

• In August 2026, Biocon Limited officially launched Yesafili™ (aflibercept-jbvf) in the United States. This medication is an FDA-approved biosimilar to Eylea® (aflibercept) 2 mg and functions as a vascular endothelial growth factor (VEGF) inhibitor to treat various eye conditions. Having received an interchangeable designation from the FDA in May 2024, Yesafili™ can be substituted for its reference product directly at the pharmacy level, depending on specific state laws.
• In June 2026, Aurobindo Pharma launched its first TheraNym biologics manufacturing plant in Borpatla, Telangana. The new contract facility features 15 KL bioreactors, modern quality control labs, and systems for downstream processing and aseptic fill-finish operations.

Biologics Market Segments

By Source

• Microbial
• Mammalian
• Others

By Product

• Monoclonal Antibodies
  • By Application
    • Diagnostic
      • Biochemical Analysis
      • Diagnostic Imaging
    • Therapeutic
      • Direct mAb Agents
      • Targeting mAb Agents
    • Protein Purification
    • Others
  • By Type
    • Murine
    • Chimeric
    • Humanized
    • Human
    • Others
• Antisense & RNAi Therapeutics
• Vaccines
• Recombinant Proteins
• Others

By Disease Category

• Oncology
• Hematological Disorders
• Infectious Disorders
• Immunological Disorders
• Cardiovascular Disorders
• Others

By Manufacturing

• In-house
• Outsourcing

By Region

• North America
  • US
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait